Author:
Ma Ning,Bansal Meena,Chu Jaime,Branch Andrea D.
Abstract
AbstractBackground and Aims:The newly proposed nomenclature for steatotic liver diseases (SLD) aims to reduce the stigma associated with “non-alcoholic fatty liver disease” (NAFLD), increase awareness, and provide a framework for delineating pathogenic pathways.Approach and Results:We projected the new nomenclature’s diagnostic scheme onto National Health and Nutrition Examination Survey (NHANES) data and determined SLD prevalence, fibrosis risk factors, subtypes, and consistency with previous classifications. Steatosis grade and fibrosis stage were estimated from vibration controlled transient elastography (VCTE). At a threshold of 240 dB/m, 62.1% [95% confidence interval (CI), 59.8-64.3%] of adults (≥ 20 years) and 30.5% (95% CI, 27.1-34.0%) of adolescents (12-19 years) had SLD. By American Gastroenterological Association criteria, 19.3 million (95% CI, 15.8-22.8) adults with SLD qualify for hepatology referral. Over 98% of adults but only 85% of adolescents with NAFLD met criteria for definite MASLD. Significant fibrosis (≥ 8.6 kPa) occurred in 13.5 million (95% CI, 10.9-16.2) adults with MASLD; risk factors varied by race and ethnicity. Significant fibrosis occurred in over 1.5 million adults without any identified LD and was associated with lead (Pb) exposure, odds ratio = 3.89 (95% CI, 2.00-7.56).Conclusions:The overarching term, SLD, changes the diagnostic algorithm and creates an umbrella classification that highlights the extraordinary prevalence of liver steatosis. The more precise nomenclature establishes a valuable patient-centric platform for research and clinical care, clarifying risk groups and risk factors, including adolescents with NAFLD but without definite MASLD and adults without SLD in whom toxic exposures may increase fibrosis risk.
Publisher
Cold Spring Harbor Laboratory
Reference24 articles.
1. Rinella ME , Lazarus JV , Ratziu V , et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Journal of hepatology. 2023.
2. A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD;Hepatology (Baltimore, Md),2023
3. Johnson CL , Paulose-Ram R , Ogden CL , et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital and health statistics Series 2, Data evaluation and methods research. 2013(161):1-24.
4. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan(®): A Comparative Study with the M Probe and Liver Biopsy;Digestive diseases and sciences,2017
5. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease;Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association,2019